Gene therapies, today and tomorrow
By supporting and encouraging evidence-based access to gene therapy, payers and other segments of U.S. society will be positioned to benefit from future advancements and biopharmaceutical breakthrough...
Read More
What’s on the horizon for nonalcoholic steatohepatitis (NASH) treatment?
The future of NASH treatment is more promising than ever with improved methods for diagnosis and new drugs in development.
Read More
The importance of a clinical-first approach to formulary development
The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.
Read More
Easing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read More
Preparing the market for the evolving biosimilar landscape
With more biosimilars and the first major influx of interchangeable inflammatory biosimilars coming to market, proactive education and outreach will be crucial for successful conversions to low-cost o...
Read More